Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sleep Wake Disorders 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Methylphenidate × 90 days × Clear all
NCT03525873 2026-04-15

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
212 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡